It has become difficult for generic companies of MSD's hyperlipidemia complex Atozet to approve items in January.

If the approval was obtained in January, the drug for data-based re-evaluation commissioned by Chong Kun Dang and the timing of the registration were the same, so that within 20 drugs could be applied. However, it is known that the time of completion was held in early March, and drug price cuts due to the cascade system became inevitable.

According to the industry on the 3rd, generics for Atozet, which had completed the preliminary review, was applied for permission on January 23, the day after the end of PMS.

Accordingly, it is known that some companies expected t